Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
about
Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesMucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapyPediatric Psoriasis.Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvementEffective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Staphylococcus aureus bacteremia with iliac artery endarteritis in a patient receiving ustekinumabCurrent and potential immune therapies and vaccines in the management of psoriasis.IL-12 protects from psoriasiform skin inflammationDoes p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.Diagnosis and treatment of pediatric psoriasis: current and future.Long-term safety of ustekinumab for psoriasis.Ustekinumab: moving the target from psoriasis to Crohn's disease.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Advances in treating psoriasis.The risk of deep fungal infections during biologic therapy for psoriasis.Biologic response modifiers and pediatric psoriasis.Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.Fungal Infections and New Biologic Therapies.Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.Immunotargeting in the management of psoriasis.Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.Late reaction to ustekinumab infusion.Efficacy and safety of ustekinumab in a patient with chronic renal failure on hemodialysis.The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient.Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.Old and New Biological Therapies for Psoriasis.Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.Safety of biologics in psoriasis.Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.Efficacy and safety of ustekinumab in adolescents.
P2860
Q26822029-037FDD27-A6CB-48B6-B969-5419A7C17B05Q26825174-4C00326F-6A5A-4893-A0AD-D5B2C402A1BBQ26991673-74882E27-A817-489E-BC75-13F9BBFC33BAQ27010562-24F705D5-7945-433A-99FF-76851D1BD729Q30234370-60470163-94F1-491F-A496-72F4603C281AQ30574065-C39F64B6-6511-49FE-A360-620237054F38Q30620977-121B2117-DD6F-4ED4-AC56-192079A58F12Q34166896-A4F9BE54-A4DC-4687-9947-C08CF86F8681Q34517278-F56C7791-4342-47EC-B3E2-8F38C3751FCCQ35263519-F38B13EE-B8EF-4111-BD09-C54CB24A3B9AQ35606402-A487C738-E045-48EA-88D6-D5E3777E9FB9Q36169782-CA576D2F-E3B9-4862-A619-28D35A5652B0Q36977772-D7EDB1BB-75A7-4722-8053-8895B8221DD8Q37465195-63F36A40-9B69-410B-BE89-30E9142D2487Q38023581-E9C2D5F6-C7A6-4FB9-B179-5A6011B80102Q38028619-9293F992-DA25-4CDE-BBCA-FF26814FAD3AQ38107168-E70E7B86-24F4-4E7E-B9A7-F4A4EE70348AQ38112783-2A97186A-9AEC-4E87-92C9-4EEE1CFB0ECBQ38177321-160CCFDF-9E48-4023-8A58-E5A6D6E22D59Q38192553-9EF5B601-AFF1-4435-B1AD-0665339D943AQ38193099-5F5C331D-134F-40F6-864F-A3D0403E8A82Q38219217-E070FAD8-4DE0-4AA5-B8FA-7CC935528FFCQ38366432-2491BC56-A7D2-4467-BA42-3530DE3D6B2DQ38748380-E06C0C6A-2BD0-474B-B56C-A3519F8CBBF6Q38749257-F4F6DDA2-5435-4810-8E9A-8344E31C0230Q38794862-928EA94B-76BD-4E64-A11E-BB46DFCBC14FQ38798137-684692F1-5472-45BF-9DB8-E3FB43E07123Q38912240-823BAB93-B775-44B7-9EC1-1823CDED8ACDQ42692900-5EBB459C-FA29-4095-96EF-BD1EF0CE563BQ42879699-D3B3152A-1EB9-4E28-B29D-B1B8BB19D6D6Q43468794-AD8A8715-7E29-4FD9-A21D-2BC7A6D82018Q44509047-D4EBD4B0-4450-44C0-85D3-16146FBD7812Q45354055-7C206B51-DBCA-4B8B-80BC-FB36412888CEQ45977850-2B2A0B95-9A7E-46F2-BEAE-F16729F224D8Q47141159-7405B37B-5548-4DC1-B300-98C30C781128Q47859049-549B84C9-67DB-49D2-B7BC-351802C06225Q48089393-64F15CDA-27B9-4004-B12D-37CD410580DAQ48144965-40C304F3-2256-479C-B421-EA71F3000347Q48478885-AE88EBA0-A043-470C-97F9-80DFE828530EQ49500789-1F64E34F-BCBD-4C91-B13C-A84B14121CA8
P2860
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Long-term safety experience of ...... se II and III clinical trials.
@en
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis
@nl
type
label
Long-term safety experience of ...... se II and III clinical trials.
@en
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis
@nl
prefLabel
Long-term safety experience of ...... se II and III clinical trials.
@en
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis
@nl
P2093
P1476
Long-term safety experience of ...... se II and III clinical trials.
@en
P2093
Alexa B Kimball
Cynthia Guzzo
Kenneth B Gordon
Kristian Reich
Ming-Chun Hsu
Newman Yeilding
Philippe O Szapary
Richard G Langley
Steven Fakharzadeh
P304
P356
10.1016/J.JAAD.2011.06.041
P407
P50
P577
2011-10-05T00:00:00Z